ADCT

ADC Therapeutics SA

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

ADC Therapeutics SA (ADCT) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Profitability (D+). The rating has held at C for 6 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
B-
Factor Score 3.0 / 5.0
Growth
C+
Factor Score 2.7 / 5.0
Profitability
D+
Factor Score 1.7 / 5.0
Momentum
C
Factor Score 2.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.8
EV / EBITDA -5.5
Rev Growth YoY 32.2%
Gross Margin 8.7%
Price Return 3M 21.4%
Price Return 12M -69.1%
Catalyst Signal 0.00
Market Cap $175.8M
TTM Revenue $84.9M
Price / Sales 2.1
ROE N/A

Historical Factor Score Progression

Held C for 6 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B- (3.0) C+ (2.7) D+ (1.7) C (2.2) C+ (2.6) C (2.4)
2026-11-10 B- (3.0) C (2.4) D+ (1.6) C (2.3) C+ (2.6) C (2.4)
2026-11-03 B- (3.0) C (2.3) D+ (1.6) C- (2.0) C+ (2.7) C (2.3)
2026-10-27 B- (3.0) C (2.3) D (1.5) C- (2.1) C+ (2.6) C (2.3)
2026-10-20 B- (3.0) C (2.3) D (1.5) C- (1.9) C+ (2.6) C (2.3)
Page 1 of 4